YHD 1023

Drug Profile

YHD 1023

Alternative Names: YHD1023

Latest Information Update: 18 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yuhan
  • Class Erectile dysfunction therapies
  • Mechanism of Action Nitric oxide synthase stimulants; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Erectile dysfunction

Most Recent Events

  • 18 Sep 2014 No development reported - Phase-II for Erectile dysfunction in South Korea (PO)
  • 01 Mar 2013 Yuhan Corporation completes a phase II trial in Erectile dysfunction in South Korea (NCT01423370)
  • 30 Nov 2011 Phase-II clinical trials in Erectile dysfunction in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top